What is it about?
The rate of bleeding among patients undergoing percutaneous coronary interventions is examined by comparing patients who received bivalirudin compared to those utilizing a closure device.
Featured Image
Why is it important?
Bleeding following PCI is associated with increased poor outcomes for patients and costs for hospitals. Those that experience bleeding post-procedure have more transfusions, more tests and longer lengths of stay. A peri-procedural treatment drug that prevents or minimizes post-procedure bleeding has the potential to significantly improve patient outcomes and decrease costs.
Perspectives
Conducting this study challenged the status quo on the issue of upfront costs versus down stream savings - a significant issue for hospitals and providers during a time of reimbursement changes and quality improvement initiatives.
Kimberly Barber
Ascension Health
Read the Original
This page is a summary of: The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions, Open Heart, August 2014, BMJ,
DOI: 10.1136/openhrt-2014-000087.
You can read the full text:
Contributors
The following have contributed to this page
